确定1型糖尿病 (T1D) 和小岛移植的有希望的免疫调节剂
Nida Ajmal1,2, Maislin C Bogart3, Palwasha Khan1,2
1Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
Journal of diabetes research
|December 30, 2024
概括
本综述探讨了1型糖尿病 (T1D) 治疗的非胰岛素免疫调节剂,重点介绍的是推迟T1D发病的特普利祖马布 (teplizumab) 等药物以及用于β细胞恢复和自身免疫反应抑制的临床试验中的其他药物.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 1型糖尿病 (T1D) 是一种自身免疫性疾病,由于β细胞的破坏导致高血糖症.
- 目前的胰岛素治疗可以控制血糖,但不能阻止T1D的进展.
- 有效的T1D治疗可能需要β细胞再生和免疫系统调节.
研究的目的:
- 审查非胰岛素药理疗法,重点关注1型糖尿病的免疫调节剂.
- 讨论正在研究的免疫调节药物,包括最近获得批准或处于临床试验后期阶段的药物.
- 提供有关这些疗法的机制,试验结果和不良影响的见解.
主要方法:
- 对T1D治疗非胰岛素免疫调节药物的文献综述.
- 从国家临床试验 (NCT) 数据库中分析临床试验数据 (3期及以上).
- 包括FDA批准的药物和用于小岛移植的药物.
主要成果:
- 确定了39种不同的免疫调节试验药物用于T1D.
- 突出了FDA批准的特利祖马布,用于延迟T1D发病 (第二阶段).
- 讨论了其他免疫调节剂,如otélixizumab,daclizumab,ladarixin,ATG,alemtuzumab,basiliximab,etanercept和reparixin在各种试验阶段和应用中.
结论:
- 免疫调节剂代表了一种有希望的治疗途径,超出了T1D的胰岛素.
- 几种免疫调节剂正在进行先进的临床试验或已被批准用于T1D管理和小岛移植.
- 对免疫调节机制和临床疗效的进一步研究对于T1D逆转至关重要.
相关概念视频
01:22Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
01:24Glucagon-like Receptor Agonists
249
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
249